Warner Music Group Corp (WMG) Stock Price Today
Aura AI Summary
Key Stats
- $14.78BMarket Cap
- -Volume
- MediaSector
- $34.7252W High
- $23.6552W Low
- -Typical Hold Time
- $18.98BEnterprise Value
- 2.68%Div Yield
- -Trading Activity
Track Warner Music Group Corp (WMG) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Warner Music Group Corp has traded between a low of $23.65 and a high of $34.72, highlighting its annual price range. Buy and sell Warner Music Group Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Most Recent News
US chip stocks fall on fears over new Chinese Kimi K3 model, despite strong earnings from TSMC and ASML.
US semiconductor stocks dropped sharply after the introduction of a new Chinese chip model called Kimi K3, which rattled investors despite strong earnings and raised guidance from major players like TSMC and ASML. The SOXX ETF fell 1.5%, reflecting b...
S&P 500 falls 1.6% as investors shift from growth to value amid inflation and geopolitical concerns
Last week, the S&P 500 dropped 1.6% as investors moved away from large-cap growth stocks toward value and defensive sectors. Energy and commodities outperformed, while technology and momentum stocks lagged due to renewed geopolitical tensions and inf...
Medicus Pharma's redesigned Teverelix study gets FDA and IRB approval, cutting costs and patient numbers significantly.
Medicus Pharma announced that its redesigned clinical study protocol for Teverelix, a next-generation hormone antagonist for men's health, has received approval from the Institutional Review Board and conditional acceptance from the FDA. The revised ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.